Farzin Haque
Stock Analyst at Jefferies
(2.69)
# 2,965
Out of 4,592 analysts
11
Total ratings
54.5%
Success rate
8.9%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Farzin Haque
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VOR Vor Biopharma | Initiated Coverage: Buy | $50 | $21.15 | +136.41% | 1 | Mar 29, 2026 | |
| RLMD Relmada Therapeutics | Initiated Coverage: Buy | $9 | $5.31 | +69.49% | 1 | Dec 21, 2025 | |
| VERA Vera Therapeutics | Maintained: Buy | $57 → $45 | $32.10 | +40.19% | 4 | Nov 26, 2025 | |
| RIGL Rigel Pharmaceuticals | Upgraded: Buy | $42 | $36.81 | +14.10% | 1 | Nov 5, 2025 | |
| NUVB Nuvation Bio | Initiated Coverage: Buy | $10 | $6.33 | +57.98% | 1 | Sep 29, 2025 | |
| HOWL Werewolf Therapeutics | Initiated Coverage: Buy | $4 | $0.3531 | +1,032.82% | 1 | Aug 4, 2025 | |
| PYXS Pyxis Oncology | Maintained: Buy | $10 → $6 | $2.65 | n/a | 2 | Mar 18, 2025 |
Vor Biopharma
Mar 29, 2026
Initiated Coverage: Buy
Price Target: $50
Current: $21.15
Upside: +136.41%
Relmada Therapeutics
Dec 21, 2025
Initiated Coverage: Buy
Price Target: $9
Current: $5.31
Upside: +69.49%
Vera Therapeutics
Nov 26, 2025
Maintained: Buy
Price Target: $57 → $45
Current: $32.10
Upside: +40.19%
Rigel Pharmaceuticals
Nov 5, 2025
Upgraded: Buy
Price Target: $42
Current: $36.81
Upside: +14.10%
Nuvation Bio
Sep 29, 2025
Initiated Coverage: Buy
Price Target: $10
Current: $6.33
Upside: +57.98%
Werewolf Therapeutics
Aug 4, 2025
Initiated Coverage: Buy
Price Target: $4
Current: $0.3531
Upside: +1,032.82%
Pyxis Oncology
Mar 18, 2025
Maintained: Buy
Price Target: $10 → $6
Current: $2.65
Upside: n/a